PMA supplement
P160048 S027: Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System, Eversense E3 Sensor, Eversense E3 Insert
FDA PMA supplement · 30-Day Notice · Senseonics, Incorporated
Key facts
| Original PMA | P160048 |
|---|---|
| Supplement number | S027 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Eversense E3 Continuous Glucose Monitoring System (CGM System) - Entire System, Eversense E3 Sensor, Eversense E3 Insert |
| Generic name | Continuous glucose monitor, implanted, adjunctive use |
| Applicant | Senseonics, Incorporated |
| Product code | QCD |
| Received date | Jan 23, 2024 |
| Decision date | Feb 22, 2024 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: